Neurobiological Technologies Inc. on Friday said it will discontinue internal development of corticotropin-releasing factor (CRF) in rheumatoid arthritis following disappointing results of a short Phase II study.

Absent a partner in RA, the company said it would focus its resources on other indications for CRF, as well as its other compounds in clinical development.